Celiac Panel: When to Order This Test

What Is the Celiac Panel?

The celiac panel is a group of serology tests that detect autoantibodies directed against gluten-related antigens and intestinal tissue. A positive result reflects an ongoing immune response to dietary gluten and suggests celiac disease, though biopsy remains the diagnostic standard. The panel typically includes tTG-IgA, endomysial antibody IgA (EMA-IgA), deamidated gliadin peptide antibodies (DGP-IgA and DGP-IgG), and total serum IgA.

What Each Marker Measures

tTG-IgA targets the enzyme tissue transglutaminase, which modifies gliadin peptides in the intestinal wall. It is the recommended first-line test by the American College of Gastroenterology (ACG) and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) [1].

EMA-IgA detects antibodies against endomysium, the connective tissue around smooth muscle. It carries near-perfect specificity (98-100%) but is read by immunofluorescence and is observer-dependent [2].

DGP-IgG is the most reliable marker when total IgA is low or absent. Because it is an IgG-class antibody, IgA deficiency does not impair its production [3].

Total serum IgA is not a celiac antibody. It is included to confirm that an apparently negative tTG-IgA is not a false negative caused by IgA deficiency [4].

Why the Panel Matters Beyond Gut Symptoms

Celiac disease is a systemic autoimmune condition. About 38% of newly diagnosed adults present without classic gastrointestinal symptoms, according to a 2020 analysis in the American Journal of Gastroenterology (N=770) [5]. Dermatitis herpetiformis, unexplained peripheral neuropathy, infertility, and recurrent pregnancy loss are all recognized extra-intestinal presentations. Missing the diagnosis in these patients delays treatment and allows ongoing intestinal damage.

When to Order the Celiac Panel

Order the celiac panel whenever clinical findings suggest malabsorption, autoimmune overlap, or known genetic risk. The ACG 2023 guideline states that serologic testing should be offered to "patients with signs or symptoms consistent with celiac disease, as well as asymptomatic individuals with conditions associated with increased celiac disease risk" [1].

Gastrointestinal Indications

Order the panel in patients with:

• Chronic diarrhea lasting more than 4 weeks without a clear cause
• Unexplained bloating, flatulence, or abdominal pain
• Steatorrhea or oily stools
• Unexplained weight loss
• Elevated transaminases without another explanation (celiac hepatitis affects roughly 40% of untreated patients) [6]

Nutritional and Hematologic Indications

Iron-deficiency anemia that does not respond to oral iron supplementation after 3 months is a high-yield indication. The duodenum is the primary site of iron absorption, and villous atrophy from celiac disease directly impairs uptake. A 2019 meta-analysis in Nutrients (N=6,026) found celiac disease in 3.4% of patients with unexplained iron-deficiency anemia, a rate roughly 6-fold higher than the general population prevalence of 0.5-1% [7].

B12 and folate deficiency follow a similar logic. Both nutrients are absorbed in the proximal small bowel, and untreated celiac disease reduces absorption capacity even when dietary intake is adequate.

Calcium and vitamin D deficiency, especially when it leads to osteopenia or osteoporosis before age 50, should also prompt celiac testing. DEXA T-scores below -2.5 in premenopausal women or men under 50 warrant a celiac panel as part of secondary osteoporosis workup [1].

Autoimmune and Endocrine Indications

Celiac disease co-occurs with autoimmune thyroid disease at a rate of 4-15% [8]. Patients with Hashimoto thyroiditis or Graves disease who have unexplained thyroid hormone fluctuations despite stable levothyroxine dosing may have undiagnosed celiac disease impairing drug absorption. The same applies to type 1 diabetes mellitus, where 5-10% of patients also carry celiac disease [9].

Additional autoimmune conditions associated with celiac disease include:

• Addison disease
• Autoimmune hepatitis
• Sjogren syndrome
• Selective IgA deficiency (which itself is a reason to use DGP-IgG rather than tTG-IgA)

Family History and Genetic Risk

First-degree relatives of confirmed celiac patients carry a 10% lifetime risk of developing the disease. The ACG recommends offering serologic screening to this group even when they are asymptomatic [1]. HLA-DQ2 and HLA-DQ8 genotyping has a role here: a negative HLA result rules out celiac disease with greater than 99% negative predictive value, making it useful when serologies are ambiguous or when someone has already adopted a gluten-free diet before testing [10].

How to Interpret Celiac Panel Results

Positive Results

A tTG-IgA value greater than 10 times the upper limit of normal (ULN) has a positive predictive value exceeding 95% for celiac disease on biopsy. The 2020 ESPGHAN guidelines allow a "no-biopsy" diagnosis in symptomatic pediatric patients when tTG-IgA exceeds 10x ULN on two separate samples AND EMA-IgA is also positive [11]. Adult guidelines still require duodenal biopsy for confirmation.

Mildly elevated tTG-IgA values (1-3x ULN) are less specific. They appear in type 1 diabetes, heart failure, inflammatory bowel disease, and liver disease. Reflex EMA-IgA testing on the same sample helps: a positive EMA alongside a mildly elevated tTG-IgA substantially increases the probability of true celiac disease.

A useful decision framework at HealthRX is the "Three-Gate Approach":

1. Gate 1 (Serology): tTG-IgA plus total serum IgA. If IgA is deficient (less than 7 mg/dL), switch to DGP-IgG.
2. Gate 2 (Reflex): If tTG-IgA is 1-10x ULN, add EMA-IgA. If tTG-IgA exceeds 10x ULN in a child with symptoms, proceed per ESPGHAN no-biopsy pathway.
3. Gate 3 (Confirmation): Upper endoscopy with at least 4 duodenal biopsies (1 from the bulb, 3-4 from the descending duodenum), graded by Marsh-Oberhuber classification.

Negative Results and False Negatives

A negative tTG-IgA on a normal total serum IgA is highly reassuring, with a negative predictive value of approximately 98% [2]. However, false negatives occur in three situations:

• IgA deficiency: Total serum IgA below 7 mg/dL renders all IgA-based tests unreliable. Use DGP-IgG instead.
• Gluten-free diet: Antibody titers fall within weeks of starting a gluten-free diet. A patient who eliminated gluten before testing may show normal serology despite active celiac disease. If clinical suspicion remains high, a gluten challenge (3-10 g of gluten per day for 2-6 weeks) is required before re-testing [1].
• Early disease or mild mucosal injury: Marsh 1 lesions (increased intraepithelial lymphocytes without villous atrophy) may not produce detectable antibody levels.

What a "Low" Celiac Panel Means

There is no clinically meaningful "low" result for celiac antibodies. A result below the laboratory's reference range simply means the test did not detect pathologic antibody levels at the time of sampling. The important exception is total serum IgA: a low or absent IgA is itself a finding that changes interpretation of the entire panel.

Normal Celiac Panel Reference Ranges

Reference ranges vary by laboratory and assay platform. The values below reflect commonly cited ranges across major reference laboratories (Quest Diagnostics, LabCorp) and published literature.

| Marker | Negative (Normal) | Weak Positive | Strong Positive | |---|---|---|---| | tTG-IgA | <4 U/mL | 4-10 U/mL | >10 U/mL | | EMA-IgA | Negative | N/A | Positive | | DGP-IgG | <20 U/mL | 20-30 U/mL | >30 U/mL | | DGP-IgA | <20 U/mL | 20-30 U/mL | >30 U/mL | | Total serum IgA | 70-400 mg/dL | N/A | <7 mg/dL = IgA deficient |

Always interpret results against the specific reference range printed on the lab report, as assay calibration differs between platforms.

How a Gluten-Free Diet Affects Panel Values

A strict gluten-free diet (GFD) is the only treatment for celiac disease. It also changes serologic markers in a predictable way, which makes the celiac panel a useful monitoring tool after diagnosis.

Expected Decline on Treatment

TTG-IgA typically falls 50% within 3-6 months of starting a strict GFD and reaches the normal range in 12-24 months in most compliant adults [12]. Children tend to normalize faster, sometimes within 6-12 months. EMA-IgA follows a similar trajectory but may normalize slightly faster.

Persistently elevated tTG-IgA after 12 months of a reported GFD suggests ongoing gluten exposure, either intentional or from cross-contamination. A dietitian review with a detailed gluten exposure assessment is appropriate before attributing treatment failure to refractory celiac disease.

Serial Monitoring Protocol

The ACG recommends repeat celiac serology at 6 and 12 months after starting the GFD, then annually if the patient is clinically well [1]. Persistently elevated antibodies after 24 months despite confirmed dietary adherence warrant repeat upper endoscopy to assess mucosal healing.

Bone density monitoring deserves attention here. Patients diagnosed with celiac-related osteoporosis may not see significant DEXA improvement for 2-3 years on the GFD, even when serology normalizes [13].

Celiac Panel in Special Populations

Children

ESPGHAN published its updated guidelines in 2020. In symptomatic children, when tTG-IgA exceeds 10x ULN and EMA-IgA is positive on a second blood sample, biopsy can be omitted. This approach was validated against biopsy results in a prospective multicenter study (N=707), showing 99.8% agreement [11]. HLA testing is optional in this pathway but reduces the false-positive rate further.

Pregnant Women

Celiac disease is associated with recurrent miscarriage and intrauterine growth restriction. A 2016 study in Alimentary Pharmacology and Therapeutics (N=1,814 pregnancies) found a 3.6-fold higher rate of adverse pregnancy outcomes in undiagnosed celiac patients compared with diagnosed and treated patients [14]. Testing is appropriate in women with unexplained recurrent pregnancy loss.

Patients With Type 1 Diabetes

The American Diabetes Association recommends screening for celiac disease at diagnosis of type 1 diabetes and again after 2 years if the initial screen is negative, with subsequent testing when symptoms arise [9]. Celiac disease complicates glycemic management by causing unpredictable glucose absorption.

Patients on Levothyroxine

Celiac-related villous atrophy reduces levothyroxine absorption by approximately 19-38%, based on pharmacokinetic studies cited in a 2017 review in Thyroid [15]. Clinicians should suspect undiagnosed celiac disease when levothyroxine dose requirements increase without a clear physiologic explanation.

What Happens After a Positive Celiac Panel

A positive celiac panel is a referral trigger, not a diagnosis. The confirmed diagnostic path runs through gastroenterology.

Confirming the Diagnosis

Upper endoscopy with at least 4-6 duodenal biopsies remains the gold standard. Biopsies are graded by the Marsh-Oberhuber classification:

• Marsh 0: Normal mucosa
• Marsh 1: Increased intraepithelial lymphocytes (IEL greater than 25 per 100 enterocytes)
• Marsh 2: IEL increase plus crypt hyperplasia
• Marsh 3a/b/c: Partial, subtotal, or total villous atrophy (diagnostic of celiac disease when combined with positive serology)

Starting the Gluten-Free Diet

The GFD should begin only after biopsy confirmation, so the endoscopist can assess baseline mucosal damage. Starting the GFD before biopsy may produce false-negative histology.

A registered dietitian with celiac experience is an essential part of the care team. Hidden gluten sources include medications, sauces, processed meats, and some oat products. Inadvertent gluten exposure from shared cooking surfaces can be enough to maintain low-grade inflammation.

Addressing Nutritional Deficiencies

Patients newly diagnosed with celiac disease should have baseline iron, ferritin, B12, folate, 25-hydroxyvitamin D, calcium, zinc, and copper checked. Deficiency replacement should proceed alongside the GFD; malabsorption may impair oral supplementation in severely affected patients, occasionally requiring parenteral iron or intramuscular vitamin D.

Conditions That Mimic a Positive Celiac Panel

Several non-celiac conditions can raise tTG-IgA to mildly abnormal levels:

• Type 1 diabetes: Transglutaminase autoantibodies appear transiently in a minority of patients.
• Liver cirrhosis: Impaired hepatic clearance of IgA complexes elevates tTG-IgA non-specifically.
• Congestive heart failure: Intestinal congestion may trigger tTG-IgA elevation without celiac disease [16].
• Inflammatory bowel disease: Crohn disease and ulcerative colitis both carry slightly increased rates of weakly positive tTG-IgA.
• Non-celiac gluten sensitivity (NCGS): Serology is negative by definition. NCGS is a clinical diagnosis after celiac disease and wheat allergy are excluded.

The EMA-IgA is far more specific than tTG-IgA for celiac disease and is positive in almost none of the conditions above. Reflexing to EMA-IgA when tTG-IgA is mildly elevated is therefore the most cost-effective step before proceeding to biopsy.

Key Questions to Ask Before Ordering the Test

Before sending a celiac panel, confirm three things with the patient:

1. Are they eating gluten? A person consuming fewer than 10 g of gluten per day (roughly 2 slices of wheat bread) may have suppressed antibody titers.
2. Do they have a history of IgA deficiency? If yes, or if there is clinical suspicion, order total serum IgA alongside tTG-IgA, or order DGP-IgG from the start.
3. Are they on immunosuppressants? Azathioprine, mycophenolate, or high-dose corticosteroids can suppress antibody production and produce false-negative results.